Robeco Institutional Asset Management B.V. lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 63.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,311 shares of the medical equipment provider’s stock after selling 26,956 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Hologic were worth $563,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Shell Asset Management Co. grew its stake in Hologic by 56.9% during the 3rd quarter. Shell Asset Management Co. now owns 38,983 shares of the medical equipment provider’s stock valued at $948,000 after purchasing an additional 14,136 shares in the last quarter. Curbstone Financial Management Corp grew its stake in Hologic by 101.2% during the 3rd quarter. Curbstone Financial Management Corp now owns 17,456 shares of the medical equipment provider’s stock valued at $640,000 after purchasing an additional 8,778 shares in the last quarter. MPS Loria Financial Planners LLC acquired a new position in shares of Hologic in the 2nd quarter worth approximately $191,000. Lord Abbett & CO. LLC grew its position in shares of Hologic by 78.8% in the 2nd quarter. Lord Abbett & CO. LLC now owns 432,716 shares of the medical equipment provider’s stock worth $19,637,000 after acquiring an additional 190,714 shares in the last quarter. Finally, USA Financial Portformulas Corp acquired a new position in shares of Hologic in the 2nd quarter worth approximately $2,949,000. Hedge funds and other institutional investors own 95.68% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/hologic-inc-holx-holdings-trimmed-by-robeco-institutional-asset-management-b-v/1675234.html.

HOLX has been the subject of several research reports. Piper Jaffray Companies reiterated a “buy” rating and issued a $51.00 target price on shares of Hologic in a research report on Friday, July 14th. Stifel Nicolaus reiterated a “buy” rating on shares of Hologic in a research report on Friday, July 14th. Deutsche Bank AG decreased their target price on Hologic from $51.00 to $49.00 and set a “buy” rating for the company in a research report on Thursday, August 3rd. Goldman Sachs Group, Inc. (The) lowered Hologic from a “conviction-buy” rating to a “buy” rating and decreased their target price for the stock from $48.00 to $47.00 in a research report on Thursday, August 3rd. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Hologic in a research report on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $47.77.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The company had revenue of $806.10 million for the quarter, compared to analyst estimates of $799.70 million. During the same period in the prior year, the company posted $0.51 EPS. The company’s revenue was up 12.4% compared to the same quarter last year.

In other news, Director Lawrence M. Levy sold 9,596 shares of the company’s stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total value of $353,228.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Lawrence M. Levy sold 7,138 shares of the stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $37.38, for a total value of $266,818.44. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,873 shares of company stock worth $898,754. Corporate insiders own 0.79% of the company’s stock.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.